Preview

Ожирение и почки: механизмы повреждения почек при ожирении

https://doi.org/10.14341/2071-8713-4939

Полный текст:

Список литературы

1. Mali D.D., Ma J.Z., Louis Т.А. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med. 1995;155:1073-1080.

2. Тареева И.Е. Механизмы прогрессирования гломерулонефрита. Тер. архив. 1996;6:5-10.

3. Швецов М.Ю. Особенности синдрома артериальной гипертонии у больных волчаночным нефритом: Дис. … канд. мед. наук. М., 1998.

4. Дедов И.И., Шестакова М.В. Диабетическая нефропатия М.: Универсум Паблишинг, 2000.

5. Koch R., Sharma A.M. Obesity and cardiovascular hemodynamic function. Curr Hyprtens Rep. 1999;1:127-130.

6. Alpert M.A., Terry B.E., Mulekar M. et al. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure and effect of weight loss. Am J Cardiol. 1997;80:736-740.

7. De Simone G., Devereux R.B., Roman. et al. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension. 1994;23:600-606.

8. Levy D., Garrisson R.J., Savage D.D. et al. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. Ann Intern Med. 1989;110:101-107.

9. Sharma A.M. Ожирение и риск сердечно сосудистых заболеваний: новые аспекты. 10th European Congress on Obesity, May 2000. Ожирение. Актуальные вопросы. 2001;5:4-6.

10. Jean-Pierre Despres. Оптимальное предупреждение коронарного риска у больных с висцеральным ожирением и дислипидемией. 10th European Congress on Obesity, May 2000. Ожирение. Актуальные вопросы. 2001;5:6-8.

11. Calle E.,Thun M., Petrelli J. et al. Body-mass index and mortality in a prospective cohort of U.S. adalts. В Engl J Med. 1999;7 (15):1097-1105.

12. Saxena A.K., Chopra R. Renal risk of an emerging «Epidemic» of obesity:the role of adipocyte-derived Factors. Dialysis and Transplantation. 2004;33:11-20.

13. Verani R.R. Obesity-associated FSGS:Pathologic features of lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kidney Dis. 1992;20:629-634.

14. Praga M., Hernndez E., Morales E. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2001;15:1790-1798.

15. Kambham N., Markowitz G.S., Valeri A.M., Un J., DfAgati V.D. Obesity-related glomerulopathy:An emerging epidemic. Kidney Int. 2001;59(4):1498-1509.

16. Kuiper J.J. Effects of weight reduction and angiotensin-converting enzyme inhibition on IgA nephropathy-associated proteinuria. Nephron. 1996;74(2):462-463.

17. Bonnet F., Deprele C., Sassolas A. et al. Excessive body weight as a new independentrisk factor for clinical and pathological progression in primary IgA-nephritis.Am J Kidney Dis. 2001;37 (4):720-727.

18. Meier-Krieshce H.U., Vaghela M., Thambuganipalle R. et al. The effect of body index on long-trem renal allograft survival. Transplantation. 1999;68 (9):1294-1297.

19. Johnson D.W., label N.M., Brown A.M. et al. The effect of obesity on renal transplantant outcomes. Transplantation. 2002;74:675-681.

20. Yamamoto S., Hanley E., Hahn A.B. et al. The impact of obesity in renal transplantation:An analysis of paired cadaver kidneys. Clin Transplant. 2002;16 (4):252-256.

21. Kasiske BL., Crosson JT:Renal disease in patients with massive obesity. Arch Intern Med. 1986;146:1105-1109.

22. Landsberg L., Krieger DR. Obesity, metabolism, and the sympathetic nervous sytem. Am J Hypertens. 1989;2:1255-1325.

23. Cortes P, Zhao X, Riser B, Narins RG. Regulation of glomerular volume in normal and partially nephrectomized rats. Am J Physiol. 1996;270:F356 -F370

24. Cortes P, Riser B, Narins RG. Glomerular hypertension and progressive renal disease:The interplay of mesangial cell stretch, cytokine formation and extracellular matrix synthesis. Contrib Nephrol. 1996;118:229-233.

25. Henegar J. R., Bigler S.A., Henegar L.K., Tyagi SС. and Hall J.E. Functional and Structural Changes in the Kidney in the Early Stages of Obesity J Am Soc Nephrol. 2001;12:1211-1217.

26. Fruhbeck G., Jebb S.A., Prentice A.M. Leptin:physiology and pathophysiology. Clin Physiol. 1998;18:399-419.

27. Wiecek A., Kokot F., Chudek J., Adamczak M. The adipose tissue - a novel endocrine organ of interest to the nephrologist. Nephrol Dial Transplant. 2002;17:191-195.

28. Бугрова С.А. Метаболический синдром:патогенез, клиника, диагностика, подходы к лечению. Русский медицинский журнал. 2001;9(2)

29. Дедов И.И., Мельниченко Г.А., Романцова Т.И. Патогенетические аспекты ожирения. Ожирение и метаболизм. 2004;1:3-9.

30. Бугрова С.А., Дзгоева Ф.Х. Висцеральное ожирение - ключевое звено метаболического синдрома. Ожирение и метаболизм. 2004;1:10-16.

31. Unger R.H. Lipotoxic Diseases. Annu Rev Mad. 2002;53:319-336.

32. Fernandez-Real J.M., Ricart W. Insulin Resistance and Chronic Cardiovascular Inflammatory Syndrome Endocrine Reviews. 2003;24 (3):278-301.

33. Martinez-Anso E., Lostao M.P., Martinez J.A. Immunohistochemical localization of leptin in rat kidney. Kidney Int. 1999;55:1129-1130.

34. Gunter W., Sheldon C., Han D.C. et al. Leptin and renal disease. Am J Kidney Dis. 2002;39:1-11.

35. Wolf G., Hamman A., Han D.C. et al. Leptin stimulates proliferation and TGF-b expression in renal glomerular endothelial cells:Potential role in glomerulosclerosis. Kidney Int. 1999;56:860-872.

36. Praga M. Obesity-a neglected culprit in renal disease Nephrol Dial Transplant. 2002;17:1157-1159.

37. Buoloumi A., Marumo Т., Lafonten M. Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J. 1999;13:1231-1238.

38. Das U. Is obesity an inflammatory condition? Nutrotion. 2001;17:953-956.

39. Sun Z., Andersson R. NF-kB activation and inhibition:a review. Shock. 2002;18:99-106.

40. Sonnenberg G.E., Krakower G.R., Kissebah A.H. A novel pathway to the manifestations of metabolic syndrom. Obesity Research. 2004;12 (2):180-192.

41. Kohan D.E. Production of endothelin-1 by rat mesamgisl cells: Regulation by tumor necrosis factor. J Lab Clin Med. 1992;119:477-484.

42. Baud L, Fouqueray В., Amrani P.C. Tumor necrosis factor alpha and mesangial cells. Kidney Int. 1992;41:600-603.

43. Allessi M.C., Peiretti F., Morange P. et al. Production of plasminogen activator inghibitor-1 by human adipose tissue:possible link between visceral fat accumulation and vascular disease. Diabetes. 1997;46:860-867.

44. Оганов Р.Г., Александров А.А. Гиперинсулинемия и артериальная гипертония:возвращаясь к выводам United Kingdom Prospective Diabetes Study. Русский медицинский журнал. 2001;7(3):6-10.

45. Segarra A., Chacon P., Martines-Eyarre С. et al. Circulating levels of plasminogen activator inhibitor type-1 tissue plasminogen activator, and thrombomodulin in hemodialysis patients:biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol. 2001;12:1255-1263.

46. Juhan-Vague I., Stephen D., Руке М. et al. Fibrinolitic Factors and the Risk of Myocardial infarction or Sudden Death in Patients with angina Pectoris. Circulation. 1996;94:2057-2063.

47. Hamano K., Iwano M., Akai Y. et al. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis. 2002;39:695-705.

48. Engeli S., Negel R., Sharma A.M. Pathophysiology of the Adipose Tissue Renin-Angiotensin System. Hypertension. 2000;35:1270.

49. Crandall DL, Herzlinger HE, Saunders BD, Krai JG. Developmental aspects of the adipose tissue renin-angiotensin system:therapeutic implications. Drug Dev Res. 1994;32:117-125.

50. Jones BH, Standridge MK, Moustaid N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology. 1997;138:1512-1519.

51. Goossens G.H., Blaak E.E., van Baak M.A. Possible involvement of the adipose tissue rennin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obesity Rev. 2003;4:43-55.

52. Sowers J.R. Insulin resistance and hypertension. Am J Phys Heart Circ Physiol. 2004;286:H1597-H1602.

53. Ardiallou R., Michael J.-B. The relative role of circulating and tissue renninangiotensis systema. Nephrol Dial Transplant. 1999;14:283-286.

54. Danser A.H., Koning M.M., Admiraal P.J. et al. Production of angiotensins I and II at tissue sites in intact pigs. Am J Physiol. 1992;263:H429-437.

55. Licata G, Scaglione R, Ganguzza A, Corrao S, Donatelli M, Parrinello G, Dichiara MA, Merlino G, Cecala MG. Central obesity and hypertension:relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects. Am J Hypertens. 1994;7:314-320.

56. Giacchetti G, Faloia E, Sardu C, Mariniello B, Garrapa GGM, Gatti C, Camilloni MA, Mantero F. Different gene expression of the RAS in human subcutaneous and visceral adipose tissue. Int J Obes Relat Metab Disord. 1999;23(Suppl 5):S71.

57. Cooper R, McFarlane Anderson N, Bennett Fl, Wilks R, Puras A, Tewksbury D, Ward R, Forrester T. ACE, AGT, and obesity, a potential pathway leading to hypertension. J Hum Hypertens. 1997;11:107-111.

58. Bruns K.D., Homma Т., Harris R.C. The intrarenal rennin-angiotensins system. Semin Nephrol. 1993;13:13-30.

59. Brenner B.M. Remission of renal disease:recounting the challenge, acquiring the goal. J. Clin. Invest. 2002;110:1753-1758.

60. Kohno M., Horio Т., Ideka M. et al. Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells. Kidney Int. 1992;42:860-866.

61. Benigni A., Zoja C, Corna D. et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney lnt.1993;44:440-444.

62. Brunner H.R. ACE inhibitors in renal disease. Kidney Int. 1992;42:463-479.

63. Медведева Т.Ю. Влияние препаратов, блокирующих ренин-ангиотензиновую систему, на прогрессирование почечной недостаточности в клинике и эксперименте: Дис. … канд. мед. наук М., 2001.

64. Wolf G. Angiotensin II: a pivotal factor in the progression of renal disease Nephrology Dialisis Transplantation. 1999;14(Suppl. 1):42-44.

65. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int1996;49:578-597.

66. Anderson S. Role of local and systemic angiotensin in diadetic renal disease. Kidney Int. 1997;52 (Suppl. 63):S107-S110.

67. Amann K., Nichols C, Tornig J. Effect of ramipril, nifedipine and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant. 1996;11:1003-1011.

68. Kriz W. Progression of glomerular disease: is podocyte the culprit? Kidney Int. 1998;54 (Suppl. 3):687-697.

69. Ravid M., Lang R., Rachmani R., Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch. Intern. Med. 1996;156:286-289.

70. Шестакова М.В., Дедов И.И., Шереметьева О.В., Ивлева А.Я. Показания к применению эналоприла при диабетической нефропатии. Клин. Фармакология и терапия. 1993;3:22-26.

71. The GISEN Group «Gruppo Italiano di Studi Epidemiologici in Nefrologia»:Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863.

72. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1992;90:766-771.

73. Метелица В.И. Блокаторы рецепторов ангиотензина II. Тер. архив. 1996;8:64-67.

74. Burnier M., Roch-Ramel F., Brunner H.R. Renal effects of angiotensin II receptor blocade in normotensive subjects. Kidney Int. 1996;49:1787-1790.

75. Ruggenetti P., Perna A., Cherardi G. et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropaties with non-nephrotic proteinuria. Lancet. 1999;353:359-364.

76. Оконова Е.Б. Влияние блокады ренин-ангиотензиновой системы на протеинурию и темп погрессирования хронического гломерулонефрита: Дис. ... канд. мед. наук М., 2001.

77. Chade A.R., Rodriguez-Porcel M., Grande J.P. et al. Atherosclerosis and lipoproteins. Mechanisms of Renal Structural Alterations in Combined Hypercholesterolemia and Renal Artery Stenosis. Arteriosclerosis, Thrombosis and Vascular Biology. 2003;23:1295.

78. Deen W.M., Maddox D.A., Robertson C.R., Brenner B.M. Dynamics of glomerular ultrafiltration in the rat. VII. Response to reduced renal mass. Am. J. Physiol. 1974;224:556-562.

79. Brenner B.M., Lawler E.V., Mackenzie H.S. The hyperfiltration theory:A paradigm shift in nephrology. Kidney Intern. 1996;49:1774-1777.

80. Brenner B.M., Mackenzie H.S. Nephron mass as a risk factor for progression of renal disease. Kidney Intern. 1997;52(Suppl 63):S124-S127.

81. Hinchcliffe S.A., Lynch M.R., Sargent P.H., Hovard C.V., Van V.D. The effect of intrauterine growth retardation on the development of renal nephrons. Br. J. Jbstet Gynecol. 1992;99:296-301.

82. Hinchcliffe S.A., HovardC.V, Lynch M.R. et al. Renal developmental arrest in sudden infant death syndrome. Pediatr Pathol. 1993;13:333-343.

83. Spencer J., Wang Z, Hoy W. Low birth weigth and and reduced renal volume in aboriginal children. Am J Kidney Dis. 2001;37:915-920.

84. Mafialich R., Reyes L, Herrera M. et al. Relationship between weigth at birth and the number and size of renal glomeruli in humans" a histomorphologic study. Kidney Int. 2000;58:770-773.

85. Pesce C, Schmidt K., Fogo A. et al. Glomerular size and the incidence of renal disease in African Americans and Caucasians J Nephrol. 1994;7:355-358.

86. Hughson M.D., Johnson K., Young R.J., Hoy W.E., Bertram J.F. Glomerular size and glomerulsclerosis:relationship to disease categories, glomerular solidification, and ischemic obsolescence. Am J Kidney Dis. 2002;39:679-688.

87. HostetterT.H., Rennke H.G., Brenner B.M. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med. 1982;72:375-380.

88. Пальцев М.А. Возможные механизмы развития гломерулосклероза при нефропатиях различного генеза. Архив патологии. 1994;6:23-29.

89. Fries J.U., Sanstrom D., Meyer T.W., Rennke J.D. Glomerular hypertrophy and epithelial cell injury are demonstrated of progressive glomerulosclerosis in the rat. Kidney Int (abstract). 1988;33:374.

90. Burton C.J., Harris K.P.G. The role of proteinuria in progression of chronic renal failure. Am J Kidney Dis. 1996;27 (6):765-775.

91. Кутырина И.М., Рогов В.А., Шестакова М.В., Зверев К.В. Гиперфильтрация как фактор прогрессирования хронических заболеваний почек. Тер. архив. 1992;6:10-15.

92. Кутырина И.М., Тареева И.Е., Шестакова М.В., Зверев К.В. Нарушение внутрипочечной гемодинамики при гломерулопатиях. Вестн. РАМН. 1995;5:47-52.

93. Gross M.-L, Ritz E., Schoof A. et al. Renal damage in the SHR/N-cp type 2 diabetes model:cjmparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Laboratory Investigation. 2003;83:1267-1277.

94. Hall JE, Brandy MW, Henegar JR, Shek EW. Abnormal kidney function as a cause and a consequence of obesity hypertension. Clin Exp Pharmacol Physiol. 1998;25:58-64.

95. Chagnac A., Weinstein Т., Korztes A. et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol. 2000;278:F817-F822

96. DeFronzo RA, Goldberg M, Agus ZS. The effects of glucose and insulin on renal electrolyte transport. J Clin Invest. 1976;58:83-90.

97. DeFronzo RA. The effect of insulin on renal sodium metabolism. Diabetologia. 1981;21:165-171.

98. Hall JE, Guyton AC. Control of sodium excretion and arterial pressure by intrarenal mechanisms and the renin-angiotensin system. In: Laragh JH, Brenner BM, eds. Hypertension:Pathophysiology, Diagnosis and Management. New York, NY:Raven Press Publishers;1990:1105-1130.

99. Sugerman H.J. Effects of increased intraabdominal pressure in severe obesity. Surg Clin North Am. 2001;81(5):1063-1075.

100. Нефрология. Руководство для врачей / под ред. И.Е. Тареевой. М. Медицина, 2000.

101. Welle S, Lilavivathana U, Campbell RG. Increased plasma norepinephrine concentration and metabolic rate following glucose ingestion in man. Metabolism. 1980;29:806-809.

102. Pratley RE, Dengel DR, Hagberg JM, Goldberg AP. Insulin resistance, hyperinsulinemia, and increased sympathetic nervous system activity associated with hypertension improve with diet and exercise. Diabetes. 1994;43(Suppl 1):46A

103. DeFronzo R., Ferrannini E. Insulin resistance, a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dislipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 1991;4 (3):173-194.

104. Grandberry M., Fonseca V. Insulin resistance syndrome: options for treatment. South Med J. 1999;92(1):2-15.

105. Алешин С. Метаболический синдром Х: состояние высокого риска. Ортомолекулярная медицина. 2003.

106. D'Amico G., Tubulointerstitium as predictor of progression of glomerular diseases. Nephron. 1999;83:289-295.

107. Diamond J. Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int. 1988;33:917-824.

108. Zavaroni I., Mazza S., Fantuzzi M. et al. Changes in insulin and lipid metabolism in males with asymptomatic hyperuricemia. J Intern Med. 1993;234:24-30.

109. Ellis D., Uoyd C, Becer D.J. et al. The changing course of diabetic nephropathy: Low-density lipoprotein cholesterol and blood pressure correlate with regression of proteinuria. Am J Kidney Dis. 1996;27:809-818.

110. Grone E.F. The role of lipids in nephrosclerosis and glomerulosclerosis. Atherosclerosis. 1994;107:1-13.

111. Remuzzi G., Ruggenetti P., Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997;51:708-712.

112. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.

113. Fine L.G., Orphanides C, Norman J.T. Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int. 1998;53 (Suppl. 65):S74-S78.

114. Hocher В., Thone-Reineke C, Bauer C, Raschak M., Neumayer H.H. The paracrine endothelin system: Pathophysiology and implication in clinical medicine. Eur J Clin Chem Biochem. 1997;35:175-189.

115. Ziyadeh FN. Significance of tubulointerstitial changes in diabetic renal disease. Kidney Int. 1996;49:10-13.

116. Melin J., Akyurek L.M., Kallskog O., Larsson E. Ischemia causes rapidly progressive nephropathy in the diabetic rat. Kidney Int. 1997;52:985-991.

117. Remuzzi G., Bertani T. Pathophysiology of progressive nephopathies. N Engl J Med. 1998;339:1448-1456.

118. Kohan D.E. Endothelin synthesis by rat tubule cells. Am J Physiol. 1991;261:F221-F226.

119. Bard K., Murray J.J., Breyer M.D. et al. Mesangial cells, glomerular and renal vascularresponses to endothelin in the rat kidney. J Clin Invest. 1989;83:708-712.

120. Ruiz-Ortega M., Gomez-Garre D., Alcazar R. et al. Involmant of angiotensin II and endothelin in matrix protein production and renal sclerosis. J Hypertens. 1994;12:551-558.

121. Kohan D.E. Endothelins in the kidney: Pysiology and pathophysiology. Am J Kidney Dis. 1993;4:493-510.

122. Kohan D.E. Endothelins in the normal and diseased kidney. Am J Kidney Dis. 1996;1:2-26.

123. Nabokov A., Amann K., Wagner J. et al. Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with renal ablation. Nephrol Dial Transplant. 1996;11:514-520.


Для цитирования:


Fedorova E.Y., Krasnova E.A., Shestakova M.V. Ожирение и почки: механизмы повреждения почек при ожирении. Ожирение и метаболизм. 2006;3(1):22-28. https://doi.org/10.14341/2071-8713-4939

For citation:


., ., . Ozhirenie i pochki: mekhanizmy povrezhdeniya pochek pri ozhirenii. Obesity and metabolism. 2006;3(1):22-28. (In Russ.) https://doi.org/10.14341/2071-8713-4939

Просмотров: 30


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)